JAN 20, 2019 6:31 PM PST

Combination Therapeutic Effective for Leishmaniasis and HIV Patients

WRITTEN BY: Nouran Amin

In a study published in PLOS Neglected Diseases, a special combination therapy has been proven for efficacy in cases of coinfection with Visceral leishmaniasis (VL) and human immunodeficiency virus (HIV). As of now, the World Health Organization (WHO) recommends AmBisome monotherapy for treatment, however, the study proposed a combination therapy of AmBisome and another drug called ‘miltefosine’ to be more effective.

Learn more about Visceral Leishmaniasis (VL) and HIV Coinfection from a patient perspective:

Research has confirmed that 30 mg/kg of AmBisome is effective in 43-70% of patients with an HIV co-infection. However, AmBisome brings the proneness of toxicity and an increased risk of death. HIV increases the incidence of VL by altering it symptoms and worsening the illness along with treatment outcomes and rates of relapse.

Séverine Blesson and team, who are working on the Drugs for Neglected Diseases Initiative in Switzerland, began a compassionate use of clinical studies in a treatment facility in Northwest Ethiopia consisting of combining AmBisome and miltefosine. Measurements of efficacy were taken according to parasite clearance at 29 days and 58 days. Results showed that after 29 days measurements for efficacy was 50% for AmBisome and 67% for the combination therapy. At 58 days, 55% efficacy was measured for the monotherapy and 88% for the combination treatment.

HIV infection remains a challenge for the control of visceral leishmaniasis (VL) control.

Credit: PLOS Collections Blog - Biology & Life Sciences

The study showed no safety concerns about the combination therapy. "The results of this randomized trial strongly support a change in the treatment recommendations for HIV-VL co-infected patients," noted the researchers—however, they do caution, "these results, even if encouraging, cannot be extrapolated to other settings without reservation."

Source: Science Daily

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 08, 2020
Cancer
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
JUN 08, 2020
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD- ...
JUN 09, 2020
Drug Discovery & Development
Arthritis Drug May Reduce COVID-19 Deaths by 45%
JUN 09, 2020
Arthritis Drug May Reduce COVID-19 Deaths by 45%
Researchers from the University of Michigan have found that tocilizumab, an immunosuppressive drug used to treat arthrit ...
JUN 25, 2020
Drug Discovery & Development
Three New Molecular Targets for Epilepsy
JUN 25, 2020
Three New Molecular Targets for Epilepsy
A study lead by scientists at FutureNeuro discovered three new drugs hold the potential for targeting epilepsy. These dr ...
JUL 19, 2020
Neuroscience
Eating Fish May Protect Brain from Air Pollution
JUL 19, 2020
Eating Fish May Protect Brain from Air Pollution
Researchers have found that a diet high in omega-3 fatty acids may prevent neurodegeneration among older women living in ...
JUL 28, 2020
Cardiology
Looking to Newborns for Help Healing Scars on the Heart
JUL 28, 2020
Looking to Newborns for Help Healing Scars on the Heart
Scars are a badge of honor to many, but they are really just a consequence of the body’s repair response. The body ...
JUL 24, 2020
Drug Discovery & Development
Profiling Technology Provides Rapid Drug Discovery
JUL 24, 2020
Profiling Technology Provides Rapid Drug Discovery
Rapid drug discovery saves lives and new technology is aiming to do just that in the fight against tuberculosis. Learn m ...
Loading Comments...